EFFICACY AND TOLERABILITY OF ENTERIC-COATED NAPROXEN IN THE TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID-ARTHRITIS - A DOUBLE-BLIND COMPARISON WITH STANDARD NAPROXEN FOLLOWED BY AN OPEN-LABEL TRIAL

被引:4
作者
BELLAMY, N
BEAULIEU, A
BOMBARDIER, C
HUANG, S
KRAAG, G
MENARD, HA
RUSSELL, AS
TANNENBAUM, H
WILLANS, M
CAMPBELL, J
机构
[1] MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA
[2] UNIV SHERBROOKE,DEPT MED,SHERBROOKE J1K 2R1,QUEBEC,CANADA
[3] UNIV ALBERTA,DEPT MED,EDMONTON T6G 2E1,ALBERTA,CANADA
[4] UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA
[5] UNIV LAVAL,DEPT MED,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
[6] CHU LAVAL,DEPT MED,QUEBEC CITY G1V 4G2,QUEBEC,CANADA
[7] UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA
[8] UNIV OTTAWA,DEPT MED,OTTAWA K1N 6N5,ONTARIO,CANADA
[9] MCGILL UNIV,DEPT MED,SARNIA,ONTARIO,CANADA
关键词
NAPROXEN; DOSAGE FORMS; ANTIINFLAMMATORY AGENTS; NONSTEROIDAL; ARTHRITIS; RHEUMATOID; OSTEOARTHRITIS;
D O I
10.1185/03007999209111531
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One hundred and twenty-three patients with osteoarthritis (n=50) or rheumatoid arthritis (n=73) were enrolled in a 6-week, double-blind, randomized, controlled, parallel trial comparing enteric-coated naproxen with standard naproxen. Ninety-eight patients subsequently entered a 20-week, open-label trial of enteric-coated naproxen. The study demonstrated that naproxen in both its standard formulation and its new enteric-coated formulation is a highly effective form of therapy for osteoarthritis and rheumatoid arthritis. The tolerability profiles of the two formulations were similar in term of the types of complaints reported. It is concluded that enteric-coated naproxen is an efficacious and well-tolerated formulation for the treatment of osteoarthritis and rheumatoid arthritis.
引用
收藏
页码:640 / 651
页数:12
相关论文
共 8 条
  • [1] A PRELIMINARY EVALUATION OF THE DIMENSIONALITY AND CLINICAL IMPORTANCE OF PAIN AND DISABILITY IN OSTEOARTHRITIS OF THE HIP AND KNEE
    BELLAMY, N
    BUCHANAN, WW
    [J]. CLINICAL RHEUMATOLOGY, 1986, 5 (02) : 231 - 241
  • [2] CAPELL HA, 1979, J RHEUMATOL, V6, P584
  • [3] FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P515
  • [4] LUGGEN ME, 1989, J RHEUMATOL, V16, P1565
  • [5] ROPES M W, 1958, Bull Rheum Dis, V9, P175
  • [6] Rosenbloom D., 1985, CLIN TRIALS RHEUMATI
  • [7] 1985, SAS USERS GUIDE STAT
  • [8] 1988, CURR MED RES OPIN, V11, P16